凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2015年第三季度报告全文

公告日期 2015-10-30
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




桂林莱茵生物科技股份有限公司

     2015 年第三季度报告




        2015 年 10 月




                                                                  1
                                                  桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




                                    第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚
假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    除下列董事外,其他董事亲自出席了审议本次季报的董事会会议
    未亲自出席董事姓名      未亲自出席董事职务      未亲自出席会议原因             被委托人姓名

姚新德                   董事                    出差                     谢永富

    公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员)张为鹏声明:保证
季度报告中财务报表的真实、准确、完整。




                                                                                                    2
                                                                   桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




                             第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                         本报告期末                           上年度末                本报告期末比上年度末增减

总资产(元)                                    1,654,012,327.12                1,500,502,076.51                            10.23%

归属于上市公司股东的净资产(元)                 776,189,434.70                      238,947,082.71                        224.84%

                                                           本报告期比上年同期                                  年初至报告期末比上
                                       本报告期                                         年初至报告期末
                                                                    增减                                           年同期增减

营业收入(元)                          173,527,897.34                      30.54%          377,043,226.29                  18.84%

归属于上市公司股东的净利润(元)         45,829,616.67                     731.46%           56,509,284.11                 178.87%

归属于上市公司股东的扣除非经常
                                         45,031,245.96                     788.17%           53,388,336.36                 262.32%
性损益的净利润(元)

经营活动产生的现金流量净额(元)           --                        --                     138,866,804.17                 202.49%

基本每股收益(元/股)                               0.31                   675.00%                      0.41               156.25%

稀释每股收益(元/股)                               0.31                   675.00%                      0.41               156.25%

加权平均净资产收益率                              6.03%                      3.47%                    10.52%                 0.75%



截止披露前一交易日的公司总股本:

截止披露前一交易日的公司总股本(股)                                                                                    437,281,362

公司报告期末至季度报告披露日股本是否因发行新股、增发、配股、股权激励行权、回购等原因发生变化且影响所有者权益
金额
√ 是 □ 否

                                                                          本报告期                       年初至报告期末

用最新股本计算的基本每股收益(元/股)                                                   0.1048                              0.1292

注:经 2015 年 9 月 15 日公司召开的 2015 年第 2 次临时股东大会审议通过,公司 2015 年半年度利润分配预案为:以总股本
145,760,454 股为基数,向全体股东每 10 股派发现金股利 0.5 元(含税),不送红股,以资本公积金向全体股东每 10 股转增
20 股。本次权益分派股权登记日为:2015 年 10 月 19 日,除权除息日为:2015 年 10 月 20 日。本次权益分派后,公司股本
变更为 437,281,362 股。


非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                           单位:元

                          项目                                     年初至报告期期末金额                          说明


                                                                                                                                      3
                                                           桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


非流动资产处置损益(包括已计提资产减值准备的冲销部分)                      -80,881.82

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          2,457,602.00
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                                 663,333.33

除上述各项之外的其他营业外收入和支出                                     -1,423,255.80

                                                                                         取得法院最终胜诉判决后,前期
其他符合非经常性损益定义的损益项目                                        1,347,150.04 预计负债(诉讼利息)冲回形成
                                                                                         的收益

减:所得税影响额                                                           -157,000.00

合计                                                                      3,120,947.75                --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、报告期末普通股股东总数及前十名普通股股东持股情况表

                                                                                                               单位:股

报告期末普通股股东总数                                                                                          21,621

                                          前 10 名普通股股东持股情况

                                                                     持有有限售条件           质押或冻结情况
       股东名称        股东性质      持股比例       持股数量
                                                                       的股份数量         股份状态         数量

秦本军               境内自然人           17.57%      25,613,504          19,210,128 质押                  25,600,000

姚新德               境内自然人            7.86%      11,453,881           9,190,411 质押                  10,200,086

梁定志               境内自然人            4.77%         6,958,149         4,700,000 质押                   5,700,000

中央汇金投资有限责
                     其他                  4.46%         6,497,200
任公司

易红石               境内自然人            3.20%         4,667,539         3,400,000 质押

天安财产保险股份有
                     其他                  2.44%         3,552,178
限公司—保赢 1 号

蒋安明               境内自然人            2.13%         3,101,576                    质押                  3,100,000

财通基金-兴业银行
—富春 182 号资产管 其他                   1.56%         2,273,242
理计划



                                                                                                                         4
                                                           桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


邹瀚枢               境内自然人             1.37%        2,000,000       2,000,000

工银瑞信基金—农业
银行—工银瑞信中证 其他                     1.33%        1,938,800
金融资产管理计划

                                      前 10 名无限售条件普通股股东持股情况

                                                                                             股份种类
              股东名称                     持有无限售条件普通股股份数量
                                                                                     股份种类           数量

中央汇金投资有限责任公司                                                 6,497,200 人民币普通股          6,497,200

秦本军                                                                   6,403,376 人民币普通股          6,403,376

天安财产保险股份有限公司—保赢 1
                                                                         3,552,178 人民币普通股          3,552,178


蒋安明                                                                   3,101,576 人民币普通股          3,101,576

姚新德                                                                   2,263,470 人民币普通股          2,263,470

梁定志                                                                   2,258,149 人民币普通股          2,258,149

工银瑞信基金—农业银行—工银瑞
                                                                         1,938,800 人民币普通股          1,938,800
信中证金融资产管理计划

南方基金—农业银行—南方中证金
                                                                         1,938,800 人民币普通股          1,938,800
融资产管理计划

中欧基金—农业银行—中欧中证金
                                                                         1,938,800 人民币普通股          1,938,800
融资产管理计划

博时基金—农业银行—博时中证金
                                                                         1,938,800 人民币普通股          1,938,800
融资产管理计划

                                   1.公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人。
                                   2.中国证券金融股份有限公司通过“工银瑞信基金-农业银行-工银瑞信中证金融资
                                   产管理计划”、“南方基金-农业银行-南方中证金融资产管理计划”、“中欧基金-农
                                   业银行-中欧中证金融资产管理计划”、“博时基金-农业银行-博时中证金融资产管
上述股东关联关系或一致行动的说
                                   理计划”、“大成基金-农业银行-大成中证金融资产管理计划”、“嘉实基金-农业银

                                   行-嘉实中证金融资产管理计划”、“广发基金-农业银行-广发中证金融资产管理计
                                   划”、“华夏基金-农业银行-华夏中证金融资产管理计划”、“银华基金-农业银行-
                                   银华中证金融资产管理计划”、“易方达基金-农业银行-易方达中证金融资产管理计
                                   划”账户合计持有公司股份 19,388,000 股,占比 13.3%。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、报告期末优先股股东总数及前十名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                     5
                                                          桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




                                         第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用

       1.资产负债表项目大幅度变动及原因:                          单位:元
         项目         期末余额         期初余额         增减比例                    变动原因
货币资金               97,791,404.73    70,246,510.73       39.21% 主要系报告期收到非公开发行股票募集资
                                                                   金以及报告期植物提取销售回款及时所致。
预付款项               36,579,005.54     4,800,560.19      661.97% 主要系报告期预付新工厂设备及工程款所
                                                                   致。
其他应收款             64,707,566.28    25,058,998.46      158.22% 主要系报告期付桂林银行投资款尚未完成
                                                                   股权登记手续所致。
其他流动资产            3,236,591.82     7,058,824.99      -54.15% 主要系报告期末增值税进项留底减少所致。
在建工程               26,361,367.57     5,329,775.00      394.61% 主要系报告期新工厂在建投入增加所致。
长期待摊费用             441,525.14       772,669.07       -42.86% 系报告期摊销计入当期损益所致。
短期借款                               142,778,719.52     -100.00% 系报告期使用募集资金补充流动资金、偿还
                                                                   银行贷款所致。
应付账款              175,305,380.44   260,204,496.09      -32.63% 系报告期支付的应付账款增加所致。
预收款项              397,259,942.91   207,655,816.46       91.31% 主要系报告期BT项目收到回购资金1.82亿
                                                                   所致。
应付职工薪酬            1,343,146.12     4,561,446.34      -70.55% 主要系报告期发放上年度计提的绩效工资
                                                                   及奖金所致。
应付利息                                  799,167.11      -100.00% 系报告期支付计提的银行利息所致。
应付股利                7,288,022.70                       100.00% 系报告期尚未支付2015年上半年现金分红
                                                                   款所致。
其他应付款              6,823,811.65   129,604,402.39      -94.73% 主要系报告期偿还1.1亿暂借款所致。
一年内到期的非流动       900,730.00    266,801,460.00      -99.66% 系报告期使用募集资金补充流动资金、偿还
负债                                                               银行贷款所致。
其他流动负债            7,620,066.74     9,472,181.12      -19.55% 系报告期BT项目收到工程发票冲销已计提
                                                                   的营业税及附加所致。
长期借款               65,000,000.00    20,000,000.00      225.00% 系报告期为满足植物提取业务原料采购需
                                                                   要增加银行长期贷款所致。
预计负债                                 5,800,074.03     -100.00% 系报告期取得法院最终判决后冲减原计提
                                                                   的预计负债。

资本公积              553,190,328.59    83,217,530.86      564.75% 系报告期非公开发行股票获得股本溢价所
                                                                   致。

其他综合收益            1,275,982.34      -545,616.51      333.86% 系报告期外币报表折算差额所致。

未分配利润             67,127,726.53    17,906,465.12      274.88% 系报告期利润增加所致。


                                                                                                            6
                                                                    桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




     2.利润表项目大幅度变动及原因                                       单位:元
        项目             本期金额               上期金额        增减比例                     变动原因
营业税金及附加                5,370,315.86       1,628,967.40       229.68% 主要系报告期BT项目个别单位工程验收后,
                                                                            计提的营业税金及附加金额增加所致。
财务费用                      2,123,367.43      23,435,927.59        -90.94% 主要系报告期BT项目资本化利息支出增加、
                                                                            短期银行贷款利息支出减少所致。
资产减值损失                  2,933,087.09         -97,985.49      3093.39% 主要系报告期计提资产减值准备增加所致。
投资收益                      3,575,899.18       8,066,250.25        -55.67% 主要系上年同期转让子公司20%股权产生
                                                                            收益所致。
营业外收入                    2,755,023.16       1,345,773.87       104.72% 主要系报告期计入当期损益的政府补助增
                                                                            加所致。
营业外支出                    1,801,558.78       1,111,218.31        62.12% 主要系赞助桂林市历史文物建设工程款所
                                                                            致。
所得税费用                    7,306,091.26       2,738,654.16       166.78% 主要系报告期BT项目按成本确认收入的单
                                                                            位工程验收后本期利润增加所致。
其他综合收益                  1,821,598.85         234,052.29       678.29% 系报告期外币折算差额所致。


     3.现金流量表项目大幅度变动及原因:                                  单位:元
        项目              本期金额             上期金额         增减比例                     变动原因
经营活动产生的现金       138,866,804.17        45,908,439.06        202.49% 主要是本年植物提取销售及时回款以及收
流量净额                                                                    BT项目1.82亿元回购资金所致。
投资活动产生的现金      -100,801,756.64        -8,985,849.82       -1021.78% 主要是支付新工厂土地款、土建工程款及设
流量净额                                                                    备款所致。
筹资活动产生的现金       -10,339,731.46       -49,075,967.50         78.93% 主要系报告期收到非公开发行股票募集资
流量净额                                                                    金以及偿还银行贷款所致。




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

    1.关于与美国嘉吉公司的合作进展情况
    2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA
与美国嘉吉股份有限公司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供
应协议》。根据协议的相关约定,该协议已经自动续约至2017年11月1日止。2015年1-9月,公司与美国嘉
吉公司执行订单总计约1,847万美元。
    2.关于BT项目的进展情况
    2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。截
至2015年9月底,BT项目累计完成工程产值约8.2亿元。目前,BT项目累计已经收到工程回购款4.32亿元。
               重要事项概述                                 披露日期                        临时报告披露网站查询索引

                                                                                       巨潮资讯网(www.cninfo.com.cn),公告
BT 项目合同实施进展公告                      2015 年 10 月 15 日
                                                                                       编号 2015-072。


                                                                                                                               7
                                                         桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项

√ 适用 □ 不适用

               承诺事由                 承诺方        承诺内容            承诺时间           承诺期限     履行情况

股改承诺

收购报告书或权益变动报告书中所作承


资产重组时所作承诺

                                                   本公司上市时,
                                                   当时持有本公
                                                   司 5%以上股份
                                                   的股东秦本军、
                                                   姚新德、杨晓涛
                                                   及蒋安明向本
                                                   公司出具了《避
                                                   免同业竞争承
                                                   诺函》,承诺:"
                                                   本人将不在中
                                                   国境内外直接
                                                   或间接从事或
                                                   参与任何在商
                                                   业上对股份公
                                     秦本军、姚新 司构成竞争的                                          截至本报告披
                                                                     2007 年 09 月 13
首次公开发行或再融资时所作承诺       德、杨晓涛及蒋 业务或活动,或                      长期履行        露日,该承诺正
                                                                     日
                                     安明          拥有与股份公                                         在履行中。
                                                   司存在竞争关
                                                   系的任何经济
                                                   实体、机构、经
                                                   济组织的权益,
                                                   或以其他任何
                                                   形式取得该经
                                                   济实体、机构、
                                                   经济组织的控
                                                   制权,或在该经
                                                   济实体、机构、
                                                   经济组织中担
                                                   任高级管理人
                                                   员或核心技术
                                                   人员。"

                                                   2015 年 7 月 8
                                                   日,公司收到董 2015 年 07 月 09 2015 年 7 月 24
其他对公司中小股东所作承诺           姚新德                                                             履行完毕
                                                   事姚新德先生 日                      日
                                                   拟增持公司股

                                                                                                                         8
                                                         桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


                                                   份的计划书,其
                                                   基于对公司未
                                                   来发展前景的
                                                   信心,计划自
                                                   2015 年 7 月 9
                                                   日起的 10 个交
                                                   易日内增持公
                                                   司股票,增持资
                                                   金不低于 280
                                                   万元人民币。

承诺是否及时履行                     是


四、对 2015 年度经营业绩的预计

2015 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2015 年度归属于上市公司股东的净利润变动幅度                            40.00%     至                 80.00%

2015 年度归属于上市公司股东的净利润变动区间(万元)                    5,825.51   至                7,489.94

2014 年度归属于上市公司股东的净利润(万元)                                                         4,161.08

                                                   得益于公司前期战略调整规划的深入落实,预计 2015 公司植物
业绩变动的原因说明                                 提取业务销售收入与上年相比将取得大幅增长,同时,莱茵投资
                                                   的 BT 项目进展顺利,部分单位工程完成验收将贡献较多利润。


五、证券投资情况

□ 适用 √ 不适用
公司报告期不存在证券投资。


六、持有其他上市公司股权情况的说明

□ 适用 √ 不适用
公司报告期未持有其他上市公司股权。


七、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


八、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


                                                                                                               9
                                                        桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                           2015 年 09 月 30 日
                                                                                                     单位:元

                 项目                        期末余额                               期初余额

流动资产:

    货币资金                                              97,791,404.73                         70,246,510.73

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                              48,842,467.29                         55,009,856.51

    预付款项                                              36,579,005.54                          4,800,560.19

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                                9,798,318.14                         9,134,984.81

    应收股利                                                3,188,313.13

    其他应收款                                            64,707,566.28                         25,058,998.46

    买入返售金融资产

    存货                                                 871,525,167.82                        825,461,445.35

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                            3,236,591.82                         7,058,824.99

流动资产合计                                            1,135,668,834.75                       996,771,181.04

非流动资产:

    发放贷款及垫款



                                                                                                           10
                                   桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


    可供出售金融资产                 33,307,092.50                        33,307,092.50

    持有至到期投资

    长期应收款                       15,960,000.00                        14,500,000.00

    长期股权投资

    投资性房地产                    260,023,458.13                       263,301,024.67

    固定资产                        132,047,577.43                       136,329,276.36

    在建工程                         26,361,367.57                         5,329,775.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                         44,606,583.52                        44,462,733.17

    开发支出

    商誉

    长期待摊费用                        441,525.14                          772,669.07

    递延所得税资产                     5,595,888.08                        5,728,324.70

    其他非流动资产

非流动资产合计                      518,343,492.37                       503,730,895.47

资产总计                           1,654,012,327.12                    1,500,502,076.51

流动负债:

    短期借款                                                             142,778,719.52

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                        175,305,380.44                       260,204,496.09

    预收款项                        397,259,942.91                       207,655,816.46

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                       1,343,146.12                        4,561,446.34

    应交税费                           6,972,578.76                        6,014,608.67




                                                                                      11
                             桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


    应付利息                                                           799,167.11

    应付股利                   7,288,022.70

    其他应付款                 6,823,811.65                        129,604,402.39

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债       900,730.00                        266,801,460.00

    其他流动负债               7,620,066.74                          9,472,181.12

流动负债合计                 603,513,679.32                      1,027,892,297.70

非流动负债:

    长期借款                  65,000,000.00                         20,000,000.00

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款               179,909,426.92                        179,909,426.92

    预计负债                                                         5,800,074.03

    递延收益                  27,826,802.00                         26,430,102.00

    递延所得税负债             1,438,226.72                          1,370,247.72

    其他非流动负债

非流动负债合计               274,174,455.64                        233,509,850.67

负债合计                     877,688,134.96                      1,261,402,148.37

所有者权益:

    股本                     145,760,454.00                        129,533,760.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                 553,190,328.59                         83,217,530.86

    减:库存股

    其他综合收益               1,275,982.34                           -545,616.51

    专项储备



                                                                               12
                                                       桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


    盈余公积                                               8,834,943.24                           8,834,943.24

    一般风险准备

    未分配利润                                           67,127,726.53                          17,906,465.12

归属于母公司所有者权益合计                              776,189,434.70                         238,947,082.71

    少数股东权益                                            134,757.46                             152,845.43

所有者权益合计                                          776,324,192.16                         239,099,928.14

负债和所有者权益总计                                   1,654,012,327.12                       1,500,502,076.51


法定代表人:秦本军                 主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


2、母公司资产负债表

                                                                                                      单位:元

                 项目                       期末余额                               期初余额

流动资产:

    货币资金                                             75,926,187.64                          67,274,233.48

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                             68,679,346.57                          82,967,085.15

    预付款项                                             32,071,853.07                            1,837,424.58

    应收利息

    应收股利                                             43,188,313.13

    其他应收款                                          177,000,958.14                          24,950,824.85

    存货                                                140,362,793.21                         191,738,113.81

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                           3,135,731.63                           7,055,405.14

流动资产合计                                            540,365,183.39                         375,823,087.01

非流动资产:

    可供出售金融资产                                     33,307,092.50                          33,307,092.50

    持有至到期投资

    长期应收款

    长期股权投资                                         39,154,924.59                         118,154,924.59

    投资性房地产                                        260,023,458.13                         263,301,024.67


                                                                                                            13
                                   桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


    固定资产                        128,205,133.96                       132,382,592.25

    在建工程                         25,990,069.57                         4,958,477.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                         43,753,945.72                        43,537,246.67

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                     5,590,732.92                        5,723,840.22

    其他非流动资产

非流动资产合计                      536,025,357.39                       601,365,197.90

资产总计                           1,076,390,540.78                      977,188,284.91

流动负债:

    短期借款                                                             122,778,719.52

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                         26,777,428.79                        37,652,290.98

    预收款项                           8,486,055.31                         423,003.86

    应付职工薪酬                        887,437.31                         3,384,339.00

    应交税费                            353,767.43                          685,272.37

    应付利息                                                                338,083.78

    应付股利                           7,288,022.70

    其他应付款                       24,767,842.38                       314,418,829.15

    划分为持有待售的负债

    一年内到期的非流动负债              900,730.00                        66,801,460.00

    其他流动负债

流动负债合计                         69,461,283.92                       546,481,998.66

非流动负债:

    长期借款                         65,000,000.00                        20,000,000.00

    应付债券




                                                                                     14
                                       桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                         179,909,426.92                          179,909,426.92

    预计负债                                                                     5,800,074.03

    递延收益                               27,826,802.00                        26,430,102.00

    递延所得税负债

    其他非流动负债

非流动负债合计                         272,736,228.92                          232,139,602.95

负债合计                               342,197,512.84                          778,621,601.61

所有者权益:

    股本                               145,760,454.00                          129,533,760.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                           553,190,328.59                           83,217,530.86

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                8,834,943.24                         8,834,943.24

    未分配利润                             26,407,302.11                       -23,019,550.80

所有者权益合计                         734,193,027.94                          198,566,683.30

负债和所有者权益总计                  1,076,390,540.78                         977,188,284.91


3、合并本报告期利润表

                                                                                     单位:元

                 项目         本期发生额                          上期发生额

一、营业总收入                             173,527,897.34                      132,927,721.04

    其中:营业收入                         173,527,897.34                      132,927,721.04

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                             121,395,905.41                      125,824,585.03



                                                                                           15
                                         桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


    其中:营业成本                        102,248,722.36                       102,502,841.10

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加                 4,512,075.07                         1,664,262.72

             销售费用                       3,279,389.63                         3,665,086.21

             管理费用                      11,141,056.34                         9,382,374.70

             财务费用                        214,662.01                          8,610,020.30

             资产减值损失

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
列)

         其中:对联营企业和合营企业
的投资收益

         汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)         52,131,991.93                         7,103,136.01

    加:营业外收入                           722,886.00                           284,001.87

         其中:非流动资产处置利得

    减:营业外支出                           150,000.00                             20,061.00

         其中:非流动资产处置损失

四、利润总额(亏损总额以“-”号填列)     52,704,877.93                         7,367,076.88

    减:所得税费用                          6,884,371.47                         1,859,656.12

五、净利润(净亏损以“-”号填列)         45,820,506.46                         5,507,420.76

    归属于母公司所有者的净利润             45,829,616.67                         5,511,938.43

    少数股东损益                               -9,110.21                            -4,517.67

六、其他综合收益的税后净额                   996,049.14                           -140,062.68

  归属母公司所有者的其他综合收益
                                             996,049.14                           -140,062.68
的税后净额

    (一)以后不能重分类进损益的其
他综合收益



                                                                                           16
                                                          桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


             1.重新计量设定受益计划净
负债或净资产的变动

             2.权益法下在被投资单位不
能重分类进损益的其他综合收益中享
有的份额

    (二)以后将重分类进损益的其他
                                                                996,049.14                          -140,062.68
综合收益

             1.权益法下在被投资单位以
后将重分类进损益的其他综合收益中
享有的份额

             2.可供出售金融资产公允价
值变动损益

             3.持有至到期投资重分类为
可供出售金融资产损益

             4.现金流量套期损益的有效
部分

             5.外币财务报表折算差额                             996,049.14                          -140,062.68

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                             46,816,555.60                         5,367,358.08

    归属于母公司所有者的综合收益
                                                             46,825,665.81                         5,371,875.75
总额

    归属于少数股东的综合收益总额                                 -9,110.21                            -4,517.67

八、每股收益:

    (一)基本每股收益                                                0.31                                 0.04

    (二)稀释每股收益                                                0.31                                 0.04

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:秦本军                      主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏


4、母公司本报告期利润表

                                                                                                       单位:元

                 项目                           本期发生额                           上期发生额

一、营业收入                                                 79,792,022.80                        69,115,403.42

    减:营业成本                                             63,242,907.38                        59,091,606.31

           营业税金及附加                                      577,240.18                           698,042.44



                                                                                                             17
                                      桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


         销售费用                       2,003,711.67                          2,142,615.91

         管理费用                       9,114,547.18                          7,800,824.26

         财务费用                       -3,966,139.00                         2,698,915.50

         资产减值损失

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                       40,000,000.00
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)     48,819,755.39                         -3,316,601.00

    加:营业外收入                        722,886.00                           284,001.87

         其中:非流动资产处置利得

    减:营业外支出                                                              20,061.00

         其中:非流动资产处置损失

三、利润总额(亏损总额以“-”号填
                                       49,542,641.39                         -3,052,660.13
列)

    减:所得税费用

四、净利润(净亏损以“-”号填列)     49,542,641.39                         -3,052,660.13

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有



                                                                                        18
                                               桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                   49,542,641.39                        -3,052,660.13

七、每股收益:

    (一)基本每股收益                                      0.34                                -0.02

    (二)稀释每股收益                                      0.34                                -0.02


5、合并年初到报告期末利润表

                                                                                             单位:元

                 项目                 本期发生额                          上期发生额

一、营业总收入                                     377,043,226.29                      317,279,573.87

    其中:营业收入                                 377,043,226.29                      317,279,573.87

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                                     317,775,302.45                      302,591,208.33

    其中:营业成本                                 270,338,524.75                      239,770,904.76

           利息支出

           手续费及佣金支出

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           营业税金及附加                            5,370,315.86                        1,628,967.40

           销售费用                                  9,165,475.46                       10,167,304.63

           管理费用                                 27,844,531.86                       27,686,089.44

           财务费用                                  2,123,367.43                       23,435,927.59

           资产减值损失                              2,933,087.09                          -97,985.49

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                     3,575,899.18                        8,066,250.25
列)

         其中:对联营企业和合营企业


                                                                                                   19
                                           桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


的投资收益

           汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)           62,843,823.02                        22,754,615.79

    加:营业外收入                            2,755,023.16                         1,345,773.87

           其中:非流动资产处置利得

    减:营业外支出                            1,801,558.78                         1,111,218.31

           其中:非流动资产处置损失             80,881.82                          1,087,037.00

四、利润总额(亏损总额以“-”号填列)       63,797,287.40                        22,989,171.35

    减:所得税费用                            7,306,091.26                         2,738,654.16

五、净利润(净亏损以“-”号填列)           56,491,196.14                        20,250,517.19

    归属于母公司所有者的净利润               56,509,284.11                        20,263,860.00

    少数股东损益                                -18,087.97                           -13,342.81

六、其他综合收益的税后净额                    1,821,598.85                          234,052.29

  归属母公司所有者的其他综合收益
                                              1,821,598.85                          234,052.29
的税后净额

    (一)以后不能重分类进损益的其
他综合收益

             1.重新计量设定受益计划净
负债或净资产的变动

             2.权益法下在被投资单位不
能重分类进损益的其他综合收益中享
有的份额

    (二)以后将重分类进损益的其他
                                              1,821,598.85                          234,052.29
综合收益

             1.权益法下在被投资单位以
后将重分类进损益的其他综合收益中
享有的份额

             2.可供出售金融资产公允价
值变动损益

             3.持有至到期投资重分类为
可供出售金融资产损益

             4.现金流量套期损益的有效
部分

             5.外币财务报表折算差额           1,821,598.85                          234,052.29

             6.其他

  归属于少数股东的其他综合收益的
税后净额



                                                                                             20
                                                         桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


七、综合收益总额                                             58,312,794.99                        20,484,569.48

    归属于母公司所有者的综合收益
                                                             58,330,882.96                        20,497,912.29
总额

    归属于少数股东的综合收益总额                                -18,087.97                           -13,342.81

八、每股收益:

    (一)基本每股收益                                                0.41                                 0.16

    (二)稀释每股收益                                                0.41                                 0.16

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


6、母公司年初到报告期末利润表

                                                                                                       单位:元

                 项目                          本期发生额                           上期发生额

一、营业收入                                                209,264,547.83                       205,163,753.24

    减:营业成本                                            168,516,336.08                       168,040,709.76

         营业税金及附加                                       1,106,001.88                          698,070.00

         销售费用                                             5,497,317.41                         6,707,814.40

         管理费用                                            22,979,699.13                        23,420,516.68

         财务费用                                            -2,307,217.60                         7,831,119.46

         资产减值损失                                         2,863,791.58                          448,601.22

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                             43,575,899.18                         8,763,774.63
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)                           54,184,518.53                         6,780,696.35

    加:营业外收入                                            2,755,023.16                         1,344,273.87

         其中:非流动资产处置利得

    减:营业外支出                                               91,558.78                            55,358.32

         其中:非流动资产处置损失                                80,881.82                            34,151.63

三、利润总额(亏损总额以“-”号填
                                                             56,847,982.91                         8,069,611.90
列)

    减:所得税费用                                             133,107.30

四、净利润(净亏损以“-”号填列)                           56,714,875.61                         8,069,611.90

五、其他综合收益的税后净额



                                                                                                             21
                                               桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


     (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

     (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                    56,714,875.61                        8,069,611.90

七、每股收益:

     (一)基本每股收益                                      0.41                                0.06

     (二)稀释每股收益                                      0.41                                0.06


7、合并年初到报告期末现金流量表

                                                                                             单位:元

                 项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                  498,915,257.74                      370,388,765.35

     客户存款和同业存放款项净增加


     向中央银行借款净增加额

     向其他金融机构拆入资金净增加


     收到原保险合同保费取得的现金

     收到再保险业务现金净额


                                                                                                   22
                                    桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


     保户储金及投资款净增加额

     处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                   6,849,692.00                          6,314,238.14

     收到其他与经营活动有关的现金     5,672,160.08                          1,416,629.56

经营活动现金流入小计                511,437,109.82                        378,119,633.05

     购买商品、接受劳务支付的现金   301,905,399.05                        272,773,894.43

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                     28,291,713.47                         28,708,984.34


     支付的各项税费                  14,968,605.87                          5,025,476.38

     支付其他与经营活动有关的现金    27,404,587.26                         25,702,838.84

经营活动现金流出小计                372,570,305.65                        332,211,193.99

经营活动产生的现金流量净额          138,866,804.17                         45,908,439.06

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金             387,586.05                          3,554,390.25

     处置固定资产、无形资产和其他
                                      1,000,000.00                          1,735,500.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
                                                                           18,075,500.00
的现金净额

     收到其他与投资活动有关的现金     6,613,000.00                          1,650,000.00

投资活动现金流入小计                  8,000,586.05                         25,015,390.25

     购建固定资产、无形资产和其他
                                     65,539,534.69                         27,667,631.07
长期资产支付的现金

     投资支付的现金                  40,262,808.00                          6,333,609.00

     质押贷款净增加额

     取得子公司及其他营业单位支付


                                                                                      23
                                             桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


的现金净额

    支付其他与投资活动有关的现金                   3,000,000.00

投资活动现金流出小计                             108,802,342.69                       34,001,240.07

投资活动产生的现金流量净额                   -100,801,756.64                          -8,985,849.82

三、筹资活动产生的现金流量:

    吸收投资收到的现金                           486,199,491.73

    其中:子公司吸收少数股东投资
收到的现金

    取得借款收到的现金                           480,000,000.00                       56,636,890.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                                                      90,259,100.00

筹资活动现金流入小计                             966,199,491.73                      146,895,990.00

    偿还债务支付的现金                           842,967,952.61                      133,490,926.15

    分配股利、利润或偿付利息支付
                                                  15,571,270.58                       26,713,113.06
的现金

    其中:子公司支付给少数股东的
股利、利润

    支付其他与筹资活动有关的现金                 118,000,000.00                       35,767,918.29

筹资活动现金流出小计                             976,539,223.19                      195,971,957.50

筹资活动产生的现金流量净额                       -10,339,731.46                      -49,075,967.50

四、汇率变动对现金及现金等价物的
                                                    -180,422.07                         170,207.61
影响

五、现金及现金等价物净增加额                      27,544,894.00                      -11,983,170.65

    加:期初现金及现金等价物余额                  70,246,510.73                       38,680,937.10

六、期末现金及现金等价物余额                      97,791,404.73                       26,697,766.45


8、母公司年初到报告期末现金流量表

                                                                                           单位:元

              项目                  本期发生额                          上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                 244,497,348.21                      223,150,567.61

    收到的税费返还                                 6,849,692.00                        6,314,238.14

    收到其他与经营活动有关的现金                   4,681,962.38                         721,640.97

经营活动现金流入小计                             256,029,002.59                      230,186,446.72

    购买商品、接受劳务支付的现金                 122,071,108.06                      151,925,990.98



                                                                                                 24
                                    桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


     支付给职工以及为职工支付的现
                                     21,293,630.73                         22,083,451.37


     支付的各项税费                   5,127,570.93                          2,915,911.88

     支付其他与经营活动有关的现金    16,093,112.95                         16,307,484.84

经营活动现金流出小计                164,585,422.67                        193,232,839.07

经营活动产生的现金流量净额           91,443,579.92                         36,953,607.65

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金             387,586.05                          3,554,390.25

     处置固定资产、无形资产和其他
                                      1,000,000.00                             35,500.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
                                                                           18,075,500.00
的现金净额

     收到其他与投资活动有关的现金     6,613,000.00                          1,650,000.00

投资活动现金流入小计                  8,000,586.05                         23,315,390.25

     购建固定资产、无形资产和其他
                                     64,908,611.69                         27,478,888.02
长期资产支付的现金

     投资支付的现金                  51,262,808.00                          6,333,609.00

     取得子公司及其他营业单位支付
的现金净额

     支付其他与投资活动有关的现金     3,000,000.00

投资活动现金流出小计                119,171,419.69                         33,812,497.02

投资活动产生的现金流量净额          -111,170,833.64                       -10,497,106.77

三、筹资活动产生的现金流量:

     吸收投资收到的现金             486,199,491.73

     取得借款收到的现金             330,000,000.00                         36,636,890.00

     发行债券收到的现金

     收到其他与筹资活动有关的现金    27,400,000.00                        101,000,000.00

筹资活动现金流入小计                843,599,491.73                        137,636,890.00

     偿还债务支付的现金             472,967,952.61                        123,490,926.15

     分配股利、利润或偿付利息支付
                                      5,806,209.47                          4,777,389.27
的现金

     支付其他与筹资活动有关的现金   336,196,688.46                         57,999,266.07

筹资活动现金流出小计                814,970,850.54                        186,267,581.49

筹资活动产生的现金流量净额           28,628,641.19                        -48,630,691.49

四、汇率变动对现金及现金等价物的       -249,433.31                           159,797.09


                                                                                      25
                                    桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文


影响

五、现金及现金等价物净增加额          8,651,954.16                        -22,014,393.52

     加:期初现金及现金等价物余额    67,274,233.48                         36,159,744.42

六、期末现金及现金等价物余额         75,926,187.64                         14,145,350.90


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。




                                                                                      26
桂林莱茵生物科技股份有限公司 2015 年第三季度报告全文



             桂林莱茵生物科技股份有限公司


             法定代表人:

                                     秦本军

                      二〇一五年十月二十八日




                                                 27
数据加载中...
prevnext
手机查看股票